Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States

By afschroeder • November 15, 2025

Charles-Schoeman C, Zueger P, McDearmon-Blondell E, Fang S, Peng Y, Oishi T, Jain M, Tesser J. Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States. Rheumatol Ther. 2025 Nov 14. doi: 10.1007/s40744-025-00808-z. Epub ahead of print. PMID: 41239038.

Tags: Biologic disease-modifying antirheumatic drug(bDMARD), Clinical Disease Activity Index(CDAI), Publications, Rheumatoid arthritis(RA), Rheumatology, Tumor necrosis factor inhibitor(TNFi)

The Role of Screentime and Family Resiliency in Overweight/Obesity in Children and Children with Developmental Disabilities Before and During COVID-19

Mudnal PS, Chuang E, Lindly OJ, Needleman J, Ganz DA, Kuo AA. The Role of Screentime and Family Resiliency in Overweight/Obesity in Children and Children[...]

Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysis

Lacy BE, Shin AS, Cangemi DJ, Yang Y, Zhao S, Rosenbaum DP. Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post[...]

High HBV Seroprotection Rates in Infants Born to People with HIV and HBV Infection in Sub-Saharan Africa

Mohtashemi N, Spaczai J, Guo R, Tseng CH, Cambou MC, Emel L, Ship H, Zhang TH, Chiu SH, Stranix-Chibanda L, Chipato T, Kintu K, Manji[...]